TNFRSF10B and pancreatic neoplasm: Oba01 links anti-DR5 antibody zaptuzumab to MMAE (a microtubule inhibitor), creating dual mechanisms: apoptosis via DR5 signaling and cytotoxicity via MMAE (77) Preclinical studies in pancreatic cancer models demonstrated anti-tumor activity.